In today’s briefing:
- Find Out When HMM’s Upcoming Early Redemption Requests Might Drop
- Tiantan (600161CH) To Acquire Weiguang (002880CH)- New King Rises in China’s Blood Products Industry
Find Out When HMM’s Upcoming Early Redemption Requests Might Drop
- Despite this pattern persisting for years, there has still been a significant price impact each time it surfaces. Therefore, we should pay attention to the upcoming CB conversion schedule.
- A consistent observation is that the price impact is most significant at the announcement of early redemption requests.
- The anticipated announcement dates for the forthcoming early redemption requests are: around May 20th (195th conversion), around September 20th (196th conversion), and around March 20th of next year (197th conversion).
Tiantan (600161CH) To Acquire Weiguang (002880CH)- New King Rises in China’s Blood Products Industry
- Guangming District State-owned Assets Supervision and Administration Bureau reached a cooperation agreement with China National Biotec to establish a joint venture, which will become the new controlling shareholder of Weiguang.
- Since Tiantan is already Sinopharm’s subsidiary, there will be horizontal competition issue in the field of blood product business between Tiantan and Weiguang, mainly due to significant business overlap.
- Some spin-offs and integrations are expected between Tiantan and Weiguang. As the reform of SOE enters a new stage, the two companies could end up very different.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
